CANY
ADAP

Caxton Associates (New York)’s Adaptimmune Therapeutics ADAP Stock Holding History

Caxton Associates (New York)’s Portfolio ADAP Stock Details ADAP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-25,713
Closed -$37.5K – 482
2022
Q4 		$37.5K Buy
+25,713
New +$41.6K ﹤0.01% 433
2022
Q3 		– Sell
-23,034
Closed -$39K – 467
2022
Q2 		$39K Buy
+23,034
New +$39.6K ﹤0.01% 538

Other funds holding ADAP

MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
LFCM
Long Focus Capital Management San Juan, Puerto Rico $3.8B AUM 7.31% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
ECM
Endurant Capital Management San Mateo, California $17.4M AUM 7.38% 1-Year Est. Return

Caxton Associates (New York)'s ADAP Position: Q1 2023 in Review

Caxton Associates (New York) sold out of Adaptimmune Therapeutics (ADAP) in Q1 2023, closing a stake of 25,713 shares — an estimated $37.5K sold.

Caxton Associates (New York) first reported a position in ADAP in Q2 2022 and held it in 2 quarters. The position peaked at $39K in Q2 2022. 65 funds tracked by Wall St. Rank hold ADAP as of Q1 2023.

  • Caxton Associates (New York) reported no remaining Adaptimmune Therapeutics position as of Q1 2023 after selling out during the quarter.
  • Caxton Associates (New York) sold 25,713 Adaptimmune Therapeutics shares in Q1 2023, an estimated $37.5K.
  • Caxton Associates (New York) first reported a position in Adaptimmune Therapeutics in Q2 2022 and held it in 2 quarters.
  • Caxton Associates (New York)'s Adaptimmune Therapeutics position peaked at $39K in Q2 2022.
  • 65 funds tracked by Wall St. Rank held Adaptimmune Therapeutics as of Q1 2023.

Based on Caxton Associates (New York)'s 13F filing for Q1 2023, filed 15 May 2023.